Logo for Herantis Pharma

Herantis Pharma Investor Relations Material

Latest events

Logo for Herantis Pharma

H2 2023

Herantis Pharma
Logo for Herantis Pharma

H2 2023

6 Mar, 2024
Logo for Herantis Pharma

H1 2023

24 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Herantis Pharma

Access all reports
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD.